2022 Fiscal Year Final Research Report
Novel method to prevent peritoneal recurrence using nuclear medicine
| Project/Area Number |
20K07704
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
北山 丈二 自治医科大学, 医学部, 教授 (20251308)
佐田 尚宏 自治医科大学, 医学部, 教授 (20261977)
鯉沼 広治 自治医科大学, 医学部, 准教授 (20382905)
宮戸 秀世 自治医科大学, 医学部, 講師 (90813163)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 腹膜播種 / マイクロRNA / 核酸医薬 |
|---|
| Outline of Final Research Achievements |
Peritoneal dissemination of advanced gastrointestinal cancer is one of the most important clinical issues.This study aimed at developing novel treatment which prevent peritoneal recurrence by correcting quantitative changes in microRNA in the peritoneal cavity.
miR-29b, which expression is downregulated in exosomes derived from the peritoneal fluid of patients with peritoneal metastasis, suppressed the mesothelial-mesenchymal transition of peritoneal mesothelial cells and suppresses the formation of peritoneal metasis in a mouse model. In addition, intraperitoneal administration of miR-29b-encapsulating exosomes resulted in an even better suppressive effect on peritoneal dissemination.
|
| Free Research Field |
がん薬物療法
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでほとんど解析されていない腹腔内液を対象とした研究の成果をもとにして、予後不良の腹膜播種に対する新たな治療法を開発することを目指した研究である。本研究を発展させることで、難治性の病態である腹膜播種をより早い段階で予防するという臨床的有用性の高い新規治療の開発につなげることが期待できる。
|
